CDC recommends 2nd COVID vaccine dose for those 65 and older
3 doses of mRNA COVID vaccine show advantage against severe outcomes
A team led by US Food and Drug Administration (FDA) researchers studying Medicare claims data during the early Omicron SARS-CoV-2 variant months conclude that a third dose of mRNA COVID-19 vaccine provides significant protection against hospitalization and death compared with two doses but wanes substantially after 4 months.
A Pfizer Covid booster vaccination gave a fit 54-year-old chronic pain, NHS doctors found. Larry Lowe, from Omagh in Northern ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two ...
But only people 12 years and older for the Pfizer-BioNTech vaccine and 18 years and older for the Moderna vaccine are currently authorized to receive this specific booster dose. The modified ...
NEW YORK — U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause ...
Prospects for Valneva's COVID-19 vaccine ... initial three-dose regimen are initially high, although they start to decline after 18 months in adult subjects. However, after a booster dose at ...
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
We assessed whether the immunogenicity of fractional doses of the 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10 [GSK] and PCV13 [Pfizer ... doses plus one booster dose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback